Patent ID: 11969459
Assignee: STEMRIM INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A  C

Claim 13:
14. A method of inhibiting a structural abnormality of the heart in cardiomyopathy, wherein the method comprises identifying a subject with cardiomyopathy and administering to the subject an effective amount of a peptide, wherein the peptide is selected from the group consisting of:
(a) a peptide consisting of the amino acid sequence described in SEQ ID NO: 1;
(b) a peptide consisting of an amino acid sequence and having an activity of stimulating migration of mesenchymal stem cells, wherein the amino acid sequence results from substitution, deletion, insertion, or addition of one amino acid in the amino acid sequence described in SEQ ID NO: 1;
(c) a peptide consisting of an amino acid sequence that shares 97% or more sequence identity with the amino acid sequence described in SEQ ID NO: 1 and having an activity of stimulating migration of mesenchymal stem cells; and
(d) a peptide consisting of an amino acid sequence and having an activity of stimulating migration of mesenchymal stem cells, wherein the amino acid sequence results from addition of one or two amino acids to the amino acid sequence described in SEQ ID NO: 1,
wherein the structural abnormality of the heart in cardiomyopathy is selected from the group consisting of cardiomegaly, cardiomyocyte hypertrophy, and myocardial fibrosis, and
wherein cardiomyopathy is selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy.